Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy

被引:20
|
作者
Harvie, MN
Campbell, IT
Thatcher, N
Baildam, A
机构
[1] S Manchester Univ Hosp NHS Trust, Univ Dept Anaesthesia, Manchester M20 2LR, Lancs, England
[2] S Manchester Univ Hosp NHS Trust, Univ Med Oncol, Manchester M20 2LR, Lancs, England
[3] S Manchester Univ Hosp NHS Trust, Univ Surg, Manchester M20 2LR, Lancs, England
关键词
body composition; dietary intake; energy expenditure; gender; nonsmall cell lung cancer; resting;
D O I
10.1046/j.1365-277X.2003.00459.x
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background Men with nonsmall cell lung cancer (NSCLC) are more susceptible to weight loss than women. The composition and aetiology of these gender specific weight changes are not known. Methods Measurements of body mass, body composition and energy balance (resting energy expenditure and energy intake) were made in 15 men and six women before and after chemotherapy for NSCLC. Results Over the course of chemotherapy minimal weight change was observed in both men and women. Men increased body fat from 25.0 +/- 5.5 to 27.9 +/- 7.9% (P < 0.05) whereas fat free mass (FFM) tended to decrease (P = 0.063). There was no change in body fat or FFM in the women. In the men resting energy expenditure decreased over the course of chemotherapy from 113.2 +/- 15.9 to 105.1 +/- 10.1% of the value predicted from the Harris Benedict equation (P < 0.05). In the women resting energy expenditure (REE) did not alter. Conclusion Over the course of chemotherapy for NSCLC, men and women appear to have different patterns of change in body composition and in energy expenditure.
引用
收藏
页码:323 / 326
页数:4
相关论文
共 50 条
  • [41] Rapid treatment reponse to pembrolizumab in nonsmall cell lung cancer (NSCLC)
    Plant, R.
    Bayne, M.
    Geldart, T.
    LUNG CANCER, 2019, 127 : S94 - S95
  • [42] Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer
    De Pauw, Rebecca
    van Meerbeeck, Jan P.
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (02) : 92 - 97
  • [43] Postoperative chemotherapy in nonsmall cell lung cancer: A systematic review
    Alam, N
    Darling, G
    Shepherd, FA
    Mackay, JA
    Evans, WK
    ANNALS OF THORACIC SURGERY, 2006, 81 (05): : 1926 - 1936
  • [44] CHALLENGES OF PREOPERATIVE CHEMOTHERAPY IN NONSMALL CELL LUNG-CANCER
    JOHNSON, DH
    LUNG CANCER, 1994, 10 : S195 - S203
  • [45] Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer
    Pirker, Robert
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (01) : 63 - 67
  • [46] Individualized chemotherapy for elderly patients with nonsmall cell lung cancer
    Gridelli, C
    Maione, P
    Barletta, E
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (02) : 199 - 203
  • [47] Observation of survival and its prognostic factors in patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Thatcher, Nicholas
    Anderson, Heather
    Bischoff, Helge G.
    van den Borne, Ben
    Langer, Frank
    Moneley, Ciara
    Pimentel, Francisco
    Riska, Henrik
    Thomas, Michael
    Visseren-Grul, Carla
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S316 - S316
  • [48] RADIOTHERAPY AND CHEMOTHERAPY FOR INOPERABLE NONSMALL CELL LUNG-CANCER
    BLEASDALE, C
    JONES, B
    POSTGRADUATE MEDICAL JOURNAL, 1995, 71 (837) : 393 - 396
  • [49] Cisplatin-gemcitabine-paclitaxel in advanced nonsmall cell lung cancer (NSCLC). A dose-finding study
    Comella, P
    Frasci, G
    Panza, N
    Pacilio, C
    Nicolella, GP
    Natale, M
    Manzione, L
    Gravina, A
    Cioffi, R
    Maiorino, L
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [50] Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
    Kobayashi, Kunihiko
    Hagiwara, Koichi
    TARGETED ONCOLOGY, 2013, 8 (01) : 27 - 33